Metsera (MTSR) Soars to All-Time High on $7.3-Billion Merger With Pfizer

Core Viewpoint - Metsera Inc. (NASDAQ:MTSR) is experiencing significant investor interest following the announcement of its acquisition by Pfizer Inc. (NYSE:PFE) for a potential value exceeding $7 billion [1][3]. Group 1: Stock Performance - Shares of Metsera Inc. reached an all-time high of $54.46 during trading before closing at $53.58, reflecting a 60.80% increase on the day [2]. Group 2: Acquisition Details - Metsera has entered into a definitive agreement with Pfizer to acquire all outstanding shares at a price of $47.50 each [3]. - The acquisition agreement includes a contingent value right (CVR) that could provide Metsera shareholders with additional payments of up to $22.50 per share, contingent on achieving specific clinical milestones [4]. Group 3: Transaction Timeline - The transaction is anticipated to close in the fourth quarter of 2025 [5].